Determinants of exacerbation risk in patients with COPD in the TIOSPIR study

被引:38
作者
Calverley, Peter M. A. [1 ]
Tetzlaff, Kay [2 ]
Dusser, Daniel [3 ]
Wise, Robert A. [4 ]
Mueller, Achim [5 ]
Metzdorf, Norbert [2 ]
Anzueto, Antonio [6 ,7 ]
机构
[1] Univ Liverpool, Inst Ageing & Chron Dis, Clin Sci Ctr, Longmoor Lane, Liverpool L9 7AL UK, Merseyside, England
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Resp Med, Ingelheim, Germany
[3] Univ Paris 05, Sorbonne Paris Cite, Hop Cochin, Dept Pneumol, Paris, France
[4] Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Biostat & Data Sci Europe, Biberach, Germany
[6] Univ Texas Hlth Sci Ctr San Antonio, Pulm Med & Crit Care, San Antonio, TX 78229 USA
[7] South Texas Vet Hlth Care Syst, San Antonio, TX USA
关键词
COPD; exacerbation; frequent exacerbators; OBSTRUCTIVE PULMONARY-DISEASE; CHRONIC-BRONCHITIS; TIOTROPIUM; SALMETEROL; ROFLUMILAST; PREVENTION; MORTALITY;
D O I
10.2147/COPD.S145814
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
100201 [内科学];
摘要
Background: Exacerbation history is used to grade the risk of COPD exacerbation, but its reliability and relationship to other risk factors and prior therapy is unclear. To examine these interrelationships, we conducted a post hoc analysis of patients in the TIOSPIR trial with. 2 years' follow-up or who died on treatment. Patients and methods: Patients were grouped by their annual exacerbation rate on treatment into nonexacerbators, infrequent, and frequent exacerbators (annual exacerbation rates 0,. 1, and. 1, respectively), and baseline characteristics discriminating among the groups were determined. We used univariate and multivariate analyses to explore the effect of baseline characteristics on risk of exacerbation, hospitalization (severe exacerbation), and death (all causes). Results: Of 13,591 patients, 6,559 (48.3%) were nonexacerbators, 4,568 (33.6%) were infrequent exacerbators, and 2,464 (18.1%) were frequent exacerbators; 45% of patients without exacerbations in the previous year exacerbated on treatment. Multivariate analysis identified baseline pulmonary maintenance medication as a predictive factor of increased exacerbation risk, with inhaled corticosteroid treatment associated with increased exacerbation risk irrespective of exacerbation history. Conclusion: Our data confirm established risk factors for exacerbation, but highlight the limitations of exacerbation history when categorizing patients and the importance of prior treatment when identifying exacerbation risk.
引用
收藏
页码:3391 / 3405
页数:15
相关论文
共 33 条
[1]
[Anonymous], 2016 GINA REP GLOB S
[2]
Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history [J].
Bateman, E. D. ;
Rabe, K. F. ;
Calverley, P. M. A. ;
Goehring, U. M. ;
Brose, M. ;
Bredenbroeker, D. ;
Fabbri, L. M. .
EUROPEAN RESPIRATORY JOURNAL, 2011, 38 (03) :553-560
[3]
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial [J].
Beeh, Kai M. ;
Glaab, Thomas ;
Stowasser, Susanne ;
Schmidt, Hendrik ;
Fabbri, Leonardo M. ;
Rabe, Klaus F. ;
Vogelmeier, Claus F. .
RESPIRATORY RESEARCH, 2013, 14
[4]
[5]
Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort [J].
Busch, Robert ;
Han, MeiLan K. ;
Bowler, Russell P. ;
Dransfield, Mark T. ;
Wells, J. Michael ;
Regan, Elizabeth A. ;
Hersh, Craig P. .
BMC PULMONARY MEDICINE, 2016, 16
[6]
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789
[7]
Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease The TORCH Experience [J].
Celli, Bartolome ;
Vestbo, Joergen ;
Jenkins, Christine R. ;
Jones, Paul W. ;
Ferguson, Gary T. ;
Calverley, Peter M. A. ;
Yates, Julie C. ;
Anderson, Julie A. ;
Willits, Lisa R. ;
Wise, Robert A. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 (03) :317-322
[8]
Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary Disease [J].
Celli, Bartolome ;
Decramer, Marc ;
Kesten, Steven ;
Liu, Dacheng ;
Mehra, Sunil ;
Tashkin, Donald P. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 180 (10) :948-955
[9]
Effects of Tiotropium on Exacerbations in Patients with COPD with Low or High Risk of Exacerbations: A Post-Hoc Analysis from the 4-Year UPLIFT (R) Trial [J].
Celli, Bartolome R. ;
Decramer, Marc ;
Asijee, Guus M. ;
Kupas, Katrin ;
Tashkin, Donald P. .
CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION, 2015, 2 (02) :122-130
[10]
Large trials, new knowledge: the changing face of COPD management [J].
De Soyza, Anthony ;
Calverley, Peter M. A. .
EUROPEAN RESPIRATORY JOURNAL, 2015, 45 (06) :1692-1703